"At 10 days, the respiratory condition was improved or stabilized in 77 (77%) patients, of whom 61 showed a significant clearing of diffuse bilateral opacities on chest x-ray and 15 were discharged from the hospital. Respiratory condition worsened in 23 (23%) patients, of whom 20 (20%) died."

"Of the 57 patients treated outside the ICU, 37 (65%) improved and suspended NIV (BCRSS 1 [IQR 0–2]), 7 (12%) patients remained stable in NIV, and 13 (23%) patients worsened (10 died, 3 were admitted to ICU)."

"Of the 43 patients treated in the ICU, 32 (74%) improved (17 of them were taken off the ventilator and were discharged to the ward), 1 (2%) remained stable (BCRSS class 5) and 10 (24%) died (all of them had BCRSS≥7 before TCZ)."

BCRSS scores decreased on average, but had a similar range of values. See figure in child node "Figure 2. Changes in Brescia COVID-19 Respiratory Severity Scale (BCRSS) among 100 severe COVID-19 patients in Brescia, Italy during 10-day follow-up after Tocilizumab (TCZ) infusion"

Three severe adverse outcomes measured: 2 patients developed septic shock and died, 1 patient developed GI perforation and required surgery